Bioelectronics Corp (BIEL)

[seven-up]

While RecoveryRx is already US FDA cleared and available for treatment following eyelid surgery, the expanded market clearance would allow use by millions of Americans annually, who undergo a surgical procedure including hip and knee joint replacements and general surgery. RecoveryRx provides an adjunctive or alternative treatment to analgesics for postoperative pain and can reduce the need for opiate analgesics during postoperative recovery. Upon its review of the submitted information, the FDA has provided written feedback and guidance for a 510(k) application to obtain expanded market clearance for treatment of postoperative pain.

Of course, this is going to save a lot of time, money, and will lead to a quick clearance.